The regenerative medicine company plans to advance its rhCollagen-based aesthetic product into clinical trials following successful safety and performance studies.
CollPlant Biotechnologies has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, clearing the path for clinical trials of the novel aesthetic medicine product.
The Israel-based regenerative medicine company’s formulation combines hyaluronic acid with a modified form of recombinant human collagen (rhCollagen) to deliver both immediate and long-lasting benefits, according to a release from the company. The filler is administered as a viscoelastic gel through a fine needle, aiming to allow physicians to sculpt precise contours that are then stabilized using CollPlant’s proprietary illumination device.
Upon light activation, the gel transitions into a semi-solid, cohesive implant that withstands gravitational and mechanical forces while maintaining the desired shape.
“The successful completion of our extensive non-clinical program marks an important milestone for CollPlant allowing us to enter clinical development of our photocurable regenerative filler,” says Yehiel Tal, chief executive officer of CollPlant, in a release. “By harnessing the unique properties of our rhCollagen technology, we aim to redefine the standard of care in aesthetic medicine with a novel solution that not only delivers immediate contouring and support but also promotes natural tissue integration for long-lasting results.”
Study Results and Manufacturing Scale-Up
CollPlant’s non-clinical program included a one-year in vivo study confirming long-term durability and biocompatibility assessments demonstrating compliance with international relevant standards. The company says the combined results establish a strong foundation for clinical advancement.
The company is now scaling and optimizing its manufacturing process to ensure readiness for the upcoming clinical trial. CollPlant’s products are based on its rhCollagen produced with the company’s proprietary plant-based genetic engineering technology.
The photocurable filler represents what the company describes as a significant development in aesthetic medicine by integrating contouring precision, structural support, and tissue regeneration into a single treatment.
Photo caption: CollPlant announces positive results from non-clinical program evaluating the photocurable dermal filler.
Photo provided: CollPlant
